<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0034-7523</journal-id>
<journal-title><![CDATA[Revista Cubana de Medicina]]></journal-title>
<abbrev-journal-title><![CDATA[Rev cubana med]]></abbrev-journal-title>
<issn>0034-7523</issn>
<publisher>
<publisher-name><![CDATA[Centro Nacional de Información de Ciencias MédicasEditorial Ciencias Médicas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0034-75232021000400007</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Características clínicas, inmunológicas y daño de órganos en pacientes con miopatías inflamatorias idiopáticas]]></article-title>
<article-title xml:lang="en"><![CDATA[Organ damage clinical and immunological characteristics in patients with idiopathic inflammatory myopathies]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Arguelles Zayas]]></surname>
<given-names><![CDATA[Ana del Carmen]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Chico Capote]]></surname>
<given-names><![CDATA[Aracelis]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Kokuina]]></surname>
<given-names><![CDATA[Elena]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Casas Figueredo]]></surname>
<given-names><![CDATA[Nelsas]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Clínico Quirúrgico &#8220;Hermanos Ameijeiras&#8221;  ]]></institution>
<addr-line><![CDATA[ La Habana]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2021</year>
</pub-date>
<volume>60</volume>
<numero>4</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S0034-75232021000400007&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S0034-75232021000400007&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S0034-75232021000400007&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  Las miopatías inflamatorias idiopáticas constituyen un grupo de enfermedades musculares caracterizadas por debilidad muscular crónica e inflamación muscular de etiología desconocida.  Objetivo:  Identificar las características clínicas e inmunológicas y su relación con el daño de órganos en los pacientes con miopatías inflamatorias idiopáticas.  Métodos:  Se realizó estudio observacional, descriptivo, transversal, en 52 pacientes con diagnóstico de miopatía inflamatoria idiopática, seguidos en la consulta protocolizada de Reumatología del Hospital Clínico Quirúrgico &#8220;Hermanos Ameijeiras&#8221; entre enero 2016 y enero 2017. Para las variables cualitativas se calcularon los porcentajes de cada grupo. Se utilizó Chi-cuadrado de Pearson (estadístico exacto de Fisher). Nivel de significación del 95 % (&#945; = 0,05) para relacionar la presencia de anticuerpos y el tipo de miopatía así como la presencia de manifestaciones clínicas de MII.  Resultados:  El 80,8 % fueron mujeres y 86,5 % de procedencia urbana. La edad media al comienzo fue 42,8 ± 13,2 años, tiempo de demora al diagnóstico de 8,8 ± 7,0 meses, tiempo medio de evolución de la enfermedad de 7,5 ± 7,1 años. El 80,8 % estaba en remisión, 50 % tenía anticuerpos específicos. La hipertensión arterial se encontró en 28,8 % de los pacientes y 23,1 % presentó neumonía intersticial. La artritis estuvo presente en 96,2 %. El 26,9 % presentaron anticuerpos específicos Jo-1 y 21,2 % Ro 52.  Conclusiones:  Predominaron los pacientes del sexo femenino en la cuarta década de la vida de procedencia urbana, los anticuerpos específicos encontrados más frecuentes fue el anti Jo-1, asociado a la presencia de neumopatía intersticial.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  Idiopathic inflammatory myopathies constitute a group of muscle diseases characterized by chronic muscle weakness and muscle inflammation of unknown etiology.  Objective:  To identify the clinical and immunological characteristics and their relationship with organ damage in patients with idiopathic inflammatory myopathies.  Methods:  An observational, descriptive, cross-sectional study was carried out in 52 patients with diagnosis of idiopathic inflammatory myopathy, followed in the protocolized consultation of Rheumatology at Hermanos Ameijeiras Clinical and Surgical Hospital from January 2016 to January 2017. For the qualitative variables, the percentages of each group were calculated. Pearson's Chi-square (Fisher's exact statistic) was used. 95% significance level (&#945; = 0.05) was used to relate the presence of antibodies and the type of myopathy as well as the presence of clinical manifestations of MII.  Results:  80.8% were women and 86.5% of urban origin. The mean age at the beginning was 42.8 ± 13.2 years, time delay to diagnosis was 8.8 ± 7.0 months, mean time of evolution of the disease of 7.5 ± 7.1 years. 80.8% were in remission, 50% had specific antibodies. Hypertension was found in 28.8% of the patients and 23.1% had interstitial pneumonia. Arthritis was present in 96.2%. 26.9% had specific Jo1 antibodies and 21.2% had Ro 52.  Conclusions:  Urban female patients in the fourth decade of life predominated, the most frequent specific antibodies found was anti-Jo-1, associated with the presence of interstitial lung disease.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[miopatía inflamatoria idiopática]]></kwd>
<kwd lng="es"><![CDATA[anticuerpos específicos Jo-1 y Ro 52]]></kwd>
<kwd lng="es"><![CDATA[dermatomiositis]]></kwd>
<kwd lng="es"><![CDATA[polimiositis]]></kwd>
<kwd lng="en"><![CDATA[idiopathic inflammatory myopathy]]></kwd>
<kwd lng="en"><![CDATA[Jo1 and Ro 52 specific antibodies]]></kwd>
<kwd lng="en"><![CDATA[dermatomyositis]]></kwd>
<kwd lng="en"><![CDATA[polymyositis]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bohan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Peter]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Polymyositis and dermatomyositis]]></article-title>
<source><![CDATA[Engl J Med]]></source>
<year>1975</year>
<volume>292</volume>
<page-range>344-77</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lundberg]]></surname>
<given-names><![CDATA[IE]]></given-names>
</name>
<name>
<surname><![CDATA[Tjarnlund]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bottai]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Werth]]></surname>
<given-names><![CDATA[VP]]></given-names>
</name>
<name>
<surname><![CDATA[Pilkington]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Visser]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2017</year>
<volume>76</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1955-64</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tsaltskan]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Aldous]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Serafi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Yakovleva]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sami]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Mamyrova]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term outcomes in juvenile myositis patients]]></article-title>
<source><![CDATA[Semin Arthritis Rheum]]></source>
<year>2020</year>
<volume>50</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>149-55</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Svensson]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Arkema]]></surname>
<given-names><![CDATA[EV]]></given-names>
</name>
<name>
<surname><![CDATA[Lundberg]]></surname>
<given-names><![CDATA[IE]]></given-names>
</name>
<name>
<surname><![CDATA[Holmqvist]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incidence and prevalence of idiopathic inflammatory myopathies in Sweden: a nationwide population-based study]]></article-title>
<source><![CDATA[Rheumatology (Oxford)]]></source>
<year>2017</year>
<volume>56</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>802-10</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Benveniste]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Stenzel]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Allenbach]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Advances in serological diagnostics of inflammatory myopathies]]></article-title>
<source><![CDATA[Curr Opin Neurol]]></source>
<year>2016</year>
<volume>29</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>662-73</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lundberg]]></surname>
<given-names><![CDATA[IE]]></given-names>
</name>
<name>
<surname><![CDATA[Tjärnlund]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bottai]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2017</year>
<volume>76</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1955-64</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oldroyd]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lilleker]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Chinoy]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Idiopathic inflammatory myopathies-a guide to subtypes, diagnostic approach and treatment]]></article-title>
<source><![CDATA[Clin Med (Lond)]]></source>
<year>2017</year>
<volume>17</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>322-8</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zamarrón de Lucas]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Carrera]]></surname>
<given-names><![CDATA[LG]]></given-names>
</name>
<name>
<surname><![CDATA[Bonilla]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Petit]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Síndrome antisintetasa: análisis de 11 casos]]></article-title>
<source><![CDATA[Med Clínic]]></source>
<year>2017</year>
<volume>148</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>166-9</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McHugh]]></surname>
<given-names><![CDATA[NJ]]></given-names>
</name>
<name>
<surname><![CDATA[Tansley]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Autoantibodies in myositis]]></article-title>
<source><![CDATA[Nat Rev Rheumatol]]></source>
<year>2018</year>
<volume>14</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>290-302</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tieu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lundberg]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Limaye]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Idiopathic inflammatory myositis]]></article-title>
<source><![CDATA[Best Prac Res Clin Rheumatol]]></source>
<year>2016</year>
<volume>30</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>149-68</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oldroyd]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lilleker]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Chinoy]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Idiopathic inflammatory myopathies -a guide to subtypes, diagnostic approach and treatment]]></article-title>
<source><![CDATA[Clin Med (Lond)]]></source>
<year>2017</year>
<volume>17</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>322-8</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Suzuki]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Integrated diagnosis project for inflammatory myopathies: an association between autoantibodies and muscle pathology]]></article-title>
<source><![CDATA[Autoimmun Rev]]></source>
<year>2017</year>
<volume>16</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>693-700</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mira Bleda]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[García Pérez]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Azahara]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[García Ortega]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Miositis necrotizante autoinmune y dermatomiositis por estatinas: un diagnóstico diferencial complejo]]></article-title>
<source><![CDATA[Rev Esp Casos Clin Med Intern (RECCMI)]]></source>
<year>2019</year>
<volume>4</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>61-3</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bevilacqua]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Earle]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Miopatías inflamatorias]]></article-title>
<source><![CDATA[Rev Med Clin Condes]]></source>
<year>2018</year>
<volume>29</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>611-21</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aussy]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Boyer]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Cordel]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dermatomyositis and immune-mediated necrotizing myopathies: a window on autoimmunity and cancer]]></article-title>
<source><![CDATA[Front Immunol]]></source>
<year>2017</year>
<volume>8</volume>
<page-range>992</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sato]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kuwana]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hirakata]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical characteristics of Japanese patients with anti OJ (anti isoleucyltRNAsynthetase) autoantibodies]]></article-title>
<source><![CDATA[Rheumatology (Oxford)]]></source>
<year>2007</year>
<volume>46</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>842-5</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shamim]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Rider]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Pandey]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Differences in idiopathic inflammatory myopathy phenotypes and genotypes between meso American mestizos and north American caucasians]]></article-title>
<source><![CDATA[Arthritis Rheum]]></source>
<year>2002</year>
<volume>46</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1885-93</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mustafa]]></surname>
<given-names><![CDATA[KN]]></given-names>
</name>
<name>
<surname><![CDATA[Dahbour]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical characteristics and outcomes of patients with idiopatic inflammatory myopathies from Jordan 1996-2009]]></article-title>
<source><![CDATA[Clin Rheumatol]]></source>
<year>2010</year>
<volume>29</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1381-5</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[O'Hanlon]]></surname>
<given-names><![CDATA[TP]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[FW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Genetic risk and protective factors for the idiopathic inflammatory myopathies]]></article-title>
<source><![CDATA[Current Rheumatol Rep]]></source>
<year>2009</year>
<volume>11</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>287-94</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gómez Graciela]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Gargiulo]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Autoantibodies in adult patients with idiopathic inflammatory]]></article-title>
<source><![CDATA[Medicina (B Aires)]]></source>
<year>2016</year>
<volume>76</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>129-34</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smoyer Tomic]]></surname>
<given-names><![CDATA[KE]]></given-names>
</name>
<name>
<surname><![CDATA[Amato]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández]]></surname>
<given-names><![CDATA[AW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incidence and prevalence of idiopathic inflammatory myopathies among commercially insured, medicare supplemental insured, and Medicaid enrolled populations: an administrative claims analysis]]></article-title>
<source><![CDATA[BMC Musculoskelet Disord]]></source>
<year>2012</year>
<volume>13</volume>
<page-range>103-4</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[González Bello]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Frequency of antinuaclear (ANA), myositis specific (MSA) and myositis associated ntiboides (MAA) in patients with idiopathic inflammatory myopathies (IIM) from Mexico]]></article-title>
<source><![CDATA[Central and South America Centers: data from the PanlarMyositis Study Group]]></source>
<year>2015</year>
<volume>29</volume>
<numero>10</numero>
<issue>10</issue>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Campo Voegeli]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Dermatomiositis y sistema del complemento: relación entre actividad de la enfermedad y grado de activación del complemento. Comparación con marcadores bioquímicos tradicionales]]></source>
<year>2013</year>
<publisher-loc><![CDATA[España ]]></publisher-loc>
<publisher-name><![CDATA[Universidad de Barcelona]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kalluru]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Hart]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Corkill]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ng]]></surname>
<given-names><![CDATA[KP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term follow-up of patients with idiopathic inflammatory myopathy at Waitemata District Health Board]]></article-title>
<source><![CDATA[N Z Med J]]></source>
<year>2016</year>
<volume>129</volume>
<numero>1429</numero>
<issue>1429</issue>
<page-range>50-6</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maraví]]></surname>
<given-names><![CDATA[TZ]]></given-names>
</name>
<name>
<surname><![CDATA[Burgos]]></surname>
<given-names><![CDATA[PI]]></given-names>
</name>
<name>
<surname><![CDATA[Prieto González]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Manifestaciones clínicas y anticuerpos asociados y específicos de miositis en 15 pacientes chilenos con dermatomiositis: serie clínica en un centro universitario]]></article-title>
<source><![CDATA[Rev Méd Chile]]></source>
<year>2020</year>
<volume>148</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marie]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Morbidity and mortality in adult polymyositis and dermatomyositis]]></article-title>
<source><![CDATA[Curr Rheumatol Rep]]></source>
<year>2012</year>
<volume>14</volume>
<page-range>275-85</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nuño]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Joven]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Carreira]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Registro de pacientes con miopatía inflamatoria de la Sociedad Madrileña de Reumatología: análisis descriptivo]]></article-title>
<source><![CDATA[Reumatol Clin]]></source>
<year>2019</year>
<volume>13</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>331-7l</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hochbert]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Feldman]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Stevens]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adult onset polymyositis/dermatomyositis: An analysis of clinical and laboratory features and survival in 76 patients with a review of the literature]]></article-title>
<source><![CDATA[Semin Arthritis Rheum]]></source>
<year>1990</year>
<volume>20</volume>
<page-range>114-20</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Xicará Sarpeque]]></surname>
<given-names><![CDATA[WE]]></given-names>
</name>
</person-group>
<source><![CDATA[Caracterización clínica de las miopatías inflamatorias]]></source>
<year>2014</year>
<publisher-loc><![CDATA[Guatemala ]]></publisher-loc>
<publisher-name><![CDATA[Universidad de San Carlos de Guatemala]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Belmonte]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Carmona]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Survival, mortality and causes of death in inflammatory myopathies]]></article-title>
<source><![CDATA[Autoimmunity]]></source>
<year>2008</year>
<volume>39</volume>
<page-range>205-15</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lega]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Fabien]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Reynaud]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome]]></article-title>
<source><![CDATA[Autoimmun Rev]]></source>
<year>2014</year>
<volume>13</volume>
<page-range>883-91</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bodoki]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Nagy-Vincze]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Griger]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Betteridge]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Szollosi]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Danko]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Four dermatomyositis-specific autoantibodies- TIF1gamma, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort]]></article-title>
<source><![CDATA[Autoimmun Rev]]></source>
<year>2014</year>
<volume>13</volume>
<page-range>1211-9</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[O&#8217;Callaghan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Labrador-Horrillo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Solans-Laque]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Myositis-specific and myositis-associated antibodies in a series of eighty-eight Mediterranean patients with idiopathic inflammatory myopathy]]></article-title>
<source><![CDATA[Arthritis Rheum]]></source>
<year>2006</year>
<volume>55</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>791-8</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ernste]]></surname>
<given-names><![CDATA[FC]]></given-names>
</name>
<name>
<surname><![CDATA[Reed]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Idiopathic inflammatory myopathies: current trends in pathogenesis, clinical features, and up-to-date treatment recommendations]]></article-title>
<source><![CDATA[Mayo Clin Proc]]></source>
<year>2013</year>
<volume>88</volume>
<page-range>83-105</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ikeda]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Takahashi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Yamaguchi]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Inasaka]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kuwana]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ikezawa]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Analysis of dermatomyositis-specific autoantibodies and clinical characteristics in Japanese patients]]></article-title>
<source><![CDATA[J Dermatol]]></source>
<year>2011</year>
<volume>38</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>973-9</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
